Clinical trial

Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis

NCT04789915

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2021-05-26

PhasePHASE1

Study timeline

Study start (actual)2021-05-26Date precision: day

Registry last updated2024-12-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Psychosisunresolved

Negative Symptoms With Primary Psychotic Disorderunresolved

Interventions

MemantineDRUG · verified · RxNorm: memantine

PlaceboDRUG

Sponsors & collaborators

Bjorn H. Ebdruplead sponsor

Lundbeck Foundationcollaborator

Danish Research Centre for Magnetic Resonancecollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04789915 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.